(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

Earnings Reaction: AZZ Disappoints; $5.25M Order Fuels Alpine 4

July 07th, 2023

AZZ Inc. (NYSE: AZZ) reported first-quarter fiscal 2024 earnings per share (EPS) of $1.14 and sales of $390.87 million, slightly below the consensus EPS of $1.16 on revenue of $396.65 million. Despite the earnings results, the company is. Read more

Market Movers: ZyVersa and Castle Biosciences Share the Spotlight

July 07th, 2023

Shares of ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) surged over 20% in early trade after the European Patent Office granted a patent (number EP 2 836 221) for its Cholesterol Efflux Mediator VAR 200 in the treatment of diabetic nephropathy/diabetic k. Read more

Morgan Stanley's Bullish Stance: Ford, General Motors, and Ferrari

July 07th, 2023

Ford Motor Company (NYSE: F), a renowned automobile manufacturer, was maintained with an Overweight rating by Morgan Stanley, who raised the price target from $14 to $16. Based on Thursday's closing price of $14.98, the adjusted price target indic. Read more

LEQEMBI Breakthrough: FDA Approves Eisai and Biogen's Alzheimer's Therapy

July 07th, 2023

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) have received FDA approval for LEQEMBI (lecanemab-irmb), a groundbreaking treatment for Alzheimer's disease (AD), the most common type of dementia. LEQEMBI is the first approved therapy to demonstrate a . Read more

Lockheed Martin Lands Lucrative Contracts Worth $136M+

July 07th, 2023

Lockheed Martin Corporation (NYSE: LMT) has secured two significant contracts with a combined value of $136,102,558. The first contract is a $122,706,700 cost-plus-fixed-fee modification to an existing contract. This modification focuses on critic. Read more

Cronos Group Gains Ground on Potential Transaction, Gorilla Technology Seals $270M+ 3Y-Deal

July 06th, 2023

Shares of Cronos Group Inc. (Nasdaq: CRON) experienced a surge of over 5% in the extended session after confirming receipt of several unsolicited indications of interest from third parties, signaling potential transactions involving Cronos and these . Read more

FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval

July 06th, 2023

Action Follows Confirmatory Trial to Verify Clinical Benefit Silver Spring, MD / CRWE PRESS RELEASE / July 06, 2023 -   Today, the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult p. Read more

Breaking: Levi Strauss Lowers Outlook, AbbVie Reveals EPS Impact

July 06th, 2023

Levi Strauss & Co. (NYSE: LEVI) has released its financial results for the second quarter of 2023. The company reported earnings per share (EPS) of $0.04, slightly exceeding the consensus estimate of $0.03. However, net revenues for the quarter were . Read more

Market Surge: Mullen Gains Momentum, Pfizer's Investment Fuels Caribou Biosciences

July 06th, 2023

Shares of Mullen Automotive, Inc. (Nasdaq: MULN) surged over 60% in pre-market trading after the company announced a $25 million stock buyback program authorized through December 31, 2023. Mullen believes that its stock is significantly undervalue. Read more

Momentum Shift: Q2 Deliveries Boost Polestar, Bullish View On Aptiv

July 06th, 2023

Polestar Automotive Holding UK PLC (Nasdaq: PSNY) has announced its global deliveries for the second quarter of 2023, with a remarkable 73% year-on-year increase in deliveries in June. The company achieved its best-ever second quarter, delivering app. Read more